signals for cardiac, vascular, and renal health. 2 In the 2012 report of the European Society of Cardiology/American College of Cardiology, the essential criterion for myocardial infarction was defined as elevated cardiac biomarkers. 3 Therefore, the accuracy of these cardiac biomarkers tests become more and more important in the diagnosis of CVD, and the advances in test technology have also contributed to the increased importance of laboratory tests. However, there is no denying that many diagnostic errors are associated with laboratory testing, and many of these errors are preventable. 4 Accordingly, evaluating the quality performance of medical laboratories has become increasingly important not only for reducing costs, but also for providing evidence of testing-related diagnostic errors. It has been demonstrated that the optimal analyzing performance and correct measurements can improve the quality of patient care. 5 Quality indicators (QIs) can be especially useful for quantifying the quality of interested aspects by comparing them against defined criteria. 6, 7 The percentage coefficient of variation (CV) can be treated as one of the QIs for monitoring the precision of measurements in the analytical phase of laboratory work. 8 To monitor the precision of measurements, laboratories should perform routine internal quality control (IQC). Additionally, ISO 15189 also requires that laboratories design IQC procedures to verify the attainment of the intended quality of results. 9 However, how can laboratories evaluate their levels of analyzing precision? Comparing
CVs with different quality specifications can let them know whether their laboratory performances have met the specific quality criterion and provide them with corresponding directions to make an effort.
Meanwhile, in this study, the national IQC investigation launched by the National Center for Clinical Laboratories (NCCL) of China in 2011
can also provide participating laboratories more useful information, including the whole national situation of precision and their own positions compared to others. For organizing this continuous survey of cardiac biomarker IQC data, we can not only have overall knowledge of the precision level of cardiac biomarker measurements, but also the tendency of CVs and pass rates against different precision specifications from 2011 to 2016. Eventually, this national survey can help laboratories set appropriate precision specifications for each analyte of cardiac biomarkers.
| MATERIALS AND METHODS

| Subjects
The subjects of this continual IQC investigation were laboratories located within different provinces in China that participated in a cardiac biomarkers EQA scheme organized by NCCL, which is the official EQA provider in China. In 2011, the number of laboratories participating in the IQC investigation for creatinine kinase MB (CK-MB) (μg/L), CK- (119/134) of laboratories submitted their IQC data for CK-MB (μg/L), CK-MB (U/L), Mb, cTnT, cTnT, and HCY in the following 5 years, respectively.
| Methods
The IQC data for cardiac biomarkers were collected in April every year from 2011 to 2016 via an additional part of the Clinet (www.clinet.
com.cn) EQA reporting system version 1.5, which was developed by NCCL in China. The survey questionnaires were distributed to participating laboratories, and they were requested to submit the IQC information, which included the manufacturers, the lot number of quality control (QC) materials, the QC rules, the number of concentration levels for in-control QC materials, the mean value of each concentration level, the current CVs of measurements, the principle of the assay, and the manufacturers of instruments, reagents, and calibrators.
The CV was calculated as the standard deviation divided by the mean value multiplied by 100. These two parameters (standard deviation and mean value) were derived from the in-control IQC results, which were judged by QC rules set by laboratories themselves. As different laboratories performed different numbers of concentration levels of QC materials, we only analyzed the CVs of level 1, for which more laboratories reported the data. Then, the percentages of laboratories meeting quality specifications (ie, pass rates)
for current CVs were calculated according to five precision criteria, including two criteria based on total error allowance (TEa) (1/3TEa and 1/4TEa) and the other three quality specifications (minimal, desirable, and optimal allowable precision criteria) derived from biologic variation data.
The acceptable CV was defined as less than corresponding precision criterion. The pass rates were defined as the ratio of "number of laboratories with acceptable CVs" to "the total number of laboratories of each group." According to different grouping rules such as year, test principle, or manufacturer of instrument, all participating laboratories could be divided into several groups for a particular biomarker. Then, pass rate for each group was calculated and compared among different groups. The appropriate precision specification was chosen from these five kinds of specifications to allow approximate 80% laboratories meet the chosen precision criterion.
| Analytical quality specifications
The 1/3TEa, 1/4TEa, and the specifications from biologic variation database including the minimum, desirable, and optimal allowable precision requirement were used as the quality criteria to evaluate the precision of IQC. The details of the quality requirements are shown in Table S1 .
| Quality specifications derived from CLIA'88
The TEa of 1/4TEa and 1/3TEa specifications was from the quality requirements (TEa) set by Clinical Laboratory Improvement Amendment (CLIA'88). 
| RESULTS
In the survey, we found that most laboratories (61.3%-79.9%) performed only one level concentration of QC measurements, and fewer laboratories (20.0%-34.4%) reported two levels of QC information (Figure 1 ). The percentage of laboratories that repeated their QC measurements increased during the study period.
As there are no standardized national QC levels for the mea- when the optimal precision criteria were applied. The analytes of CK-MB(U/L) and cTnI had a satisfactory result, for which the acceptable laboratories whose current CVs met the 1/3TEa specification were above 80% (81.5%-90.1% for cTnI; 86.6%-91.3% for
Similarly, the percentages varied greatly from 16.0%
T A B L E 1 Number of participant laboratories, distribution of current CVs, and percentages of laboratories meeting quality specifications (%) (cTnI in 2012) to 52.5% (CK-MB(U/L) in 2012) when the optimal allowable precision specification was used. Frustratingly, there was still an analyte (ie, HCY) with a performance that was not satisfactory, such that the percentages of laboratories whose CVs met the 1/3TEa specification were below 80% (71.3%-79.8%). There was no significant difference in current CVs for all cardiac biomarkers among years from 2011 to 2016 (all P > .05). See Table 1 for more information.
| Setting appropriate quality specification for analytical precision
According to the precision performance of current CVs in these 6 years, the quality specifications of analytical precision for CK-MB) (μg/L), CK-MB (U/L), Mb, cTnI, cTnT, and HCY were set as current CVs less than 9.20% (desirable), 9.90% (desirable), 7.50%
(1/4TEa), 10.54% (minimum), 7.63% (optimal), and 6.67% (1/3TEa), respectively.
| Precision analysis from test principles
As shown in Figure 2 , the test principles of
Mb, cTnT, and HCY used by most laboratories were the electrochemiluminescence assay (ECLA), the inhibition immunoassay (IIA), the ECLA, the ECLA, and the enzymatic cycling assay (ECA), respectively. The main testing method of cTnI changed substantially over 6 years. Additionally, some principles of the assay were eliminated. For example, the chemiluminescence immunoassay (CLA) was not used in HCY testing since 2015. Additionally, some new methods, such as the dot immunogold filtration assay (DIGFA), were introduced into laboratories and used for testing cardiac biomarkers after 2011. In addition, Table 2 shows the detailed information on current CVs grouped by test principles. Although the CVs among different groups divided by principles of assays were not significantly different every year, and although there is no consistent trend for CVs of each group from 2011 to 2016, we found that ECLA had the minimum CVs for each analyte every year (all P < .001).
| Precision analysis by instrument manufacturers
The manufacturers of instruments used by laboratories mainly include Abbott, Beckman, Roche, Siemens, Lepu (Beijing), and Hitachi.
Beckman and Roche had bigger proportions than other instrument producers for each analyte.
T A B L E 3 Acceptable laboratories with desirable precision specification from manufacturers of instruments
Manufacturers of the instruments
Percentage of laboratories meeting desirable precision specification %(n/N) Further analysis of the percentages of laboratories meeting desirable precision criteria indicated that the pass rates of different manufacturers were not significantly different (P > .05) in the same year except that Roche held higher pass rates for CK-MB(U/L) (P < .001), and the pass rates of a certain instrument manufacturer were also not significantly different among different years.
Surprisingly, the producer of Lepu (Beijing) had a very variable rate (eg, ranging from 27.3% to 100% for Mb). For more information, see Table 3 .
| Investigation of IQC practice
In the survey, laboratories were asked to report what control rules they used. We found that the constituent ratio of control rules had obviously changed (Figure 3 ). Fewer and fewer laboratories did not understand how to choose QC rules, while more and more laboratories began to use combined QC rules from 1 2s ,1 3s , 2 2s , R 4s , 4 1s , and 10 X in a period between 2011 and 2016.
The IQC frequency or average time interval between two IQC measurements was calculated according to the submitted number of IQC results per month. Most laboratories performed one QC run every 1-2 days (>60%), and fewer laboratories could do more than one QC run every day (<10%). For more information, see Figure 4 .
| DISCUSSION
The program described in this manuscript is the first national continuous long-term survey on IQC of cardiac biomarker measurements in Among these six analytes of cardiac biomarkers, cTnT had the most satisfactory performance, with the annual average passing rates against 1/3TEa, 1/4Tea, and specifications based on biologic variation including minimum, desirable, and optimal specification being up to 95.6%, 82.6%, 99.8%, 99.7%, and 83.8%, respectively. In contrast, HCY got the lowest pass rates based on these five quality specifications every year, and the mean annuals rates were only approximately 76.6%, 56.3%, 73.5%, 42.0%, and 10.8%, respectively.
The great difference among these two analytes is due to several factors, such as the inherent performance of the analytical system composed of an instrument, calibration and reagent, principles of the assay, IQC practice, including QC materials, rules and frequency, operation of laboratory practitioners, and so on. Therefore, laboratory quality management should require certain actions, such as training staff, compiling a standard operating procedure (SOP) of specific analyte measurement, calibrating instruments, or changing reagents to enhance the performance of the analytes that did not have satisfactory results.
Quality indicators as stated in ISO 15189 are "a measure of the degree to which a set of inherent characteristics fulfills requirements". Generally, a model higher in the hierarchy may be given high priority, so minimum, desirable, and optimal precision requirements derived from biologic variation data seem more reasonable for IQC precision evaluation.
As we can see, the pass rates against the optimal specification were all very low for these six kinds of cardiac markers. When the minimum specification was employed, the precision performance became the best with even a 100% pass rate for cTnT measurement. It reminds us of the fact that these two extreme criteria (ie, too stringent or loose)
may not be suitable as precision criteria for cardiac markers. Therefore, organizers such as the NCCL of China should choose an appropriate quality requirement according to the performance that a specific analyte can achieve nationwide, and laboratories should also choose suitable precision criteria by comparing their CVs with our data. After continuous investigation of current CVs of cardiac biomarkers and precision analysis of it, we can set quality specifications for these six analytes. To allow 80% of laboratories to meet the precision criteria, we can choose a desirable specification (CV% < 9.20%) for CK-MB(μg/L), a desirable specification (CV% < 9.90%) for CK-MB(U/L), 1/4TEa (CV% < 7.50%) for Mb, 1/3TEa (CV% < 7.03%) for cTnI, and an optimal specification (CV% < 7.63%) for cTnT and 1/3TEa (CV% < 6. 67%) for HCY. Furthermore, these precision specifications can be updated with an annual IQC investigation in the future. Only the IQC rules and frequency were set according to the laboratory's own quality performance, and the IQC plays an effective role in monitoring the accuracy of testing results.
Unfortunately, we did not find a consistent changing tendency for current CVs from 2011 to 2016. Some reasons could be attributed to the results. First, testing methods for cardiac biomarker examination may have not been improved over the last few years. Second, the QC process used to monitor the stability of the analytical system may also maintain the same approach. Third, it may be the main reason that laboratories did not recognize the importance of quality assurance by controlling the CVs within the limits of requirements, so laboratories did not take any actions to improve analytical precision at all. Finally, it may be the results of small sample size which is also a disadvantage of this investigation. Meanwhile, we did not distribute harmonized national QC materials, so the inherent essence of QC materials such as homogeneity and stability may be different among laboratories, which may lead to the variation of CVs. It was also the main deficiencies of the research. Additionally, laboratories must change the QC material lots from 2011 to 2016, so the difference in the different QC material lots can also lead to big changes in CVs. Our previous investigation on hemoglobin A1c has shown that CVs were influenced by vendors of QC materials. 24 It is a good beginning and a meaningful thing for NCCL in China to collect the IQC data from EQA participants using an additional part of EQA network platform and conducting some further statistical analysis although there were many limitations that existed in this national continual survey on IQC practice for cardiac biomarkers. However, we can conclude that the measurement precision of laboratories in China has yet to be improved, especially for some analytes, such as HCY. Laboratories can choose the quality specifications established in the paper that can be updated when necessary or set the appropriate quality specifications for themselves and then strive for it.
